-
Mashup Score: 0The Impact of Darolutamide on Dose Modification of mHSPC - 11 month(s) ago
Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer - 12 month(s) ago
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer - 12 month(s) ago
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Brenda Martone Highlights Nursing Considerations With Darolutamide in Prostate Cancer - 12 month(s) ago
Brenda Martone MSN, ANP-BC, AOCNP, discusses what nurses need to know about safely treating patients with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Neal Shore, MD, discusses the long-term exposure analysis of darolutamide in the phase 3 ARAMIS Rollover trial for patients with nonmetastatic castration-resistant prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study - 1 year(s) ago
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Arash Rezazadeh Kalebasty Discusses Darolutamide Combination Safety in the ARASENS Study - 1 year(s) ago
Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0darolutamide | CADTH - 1 year(s) ago
( Last Updated : December 1, 2022) Generic Name: darolutamide …
Source: www.cadth.caCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 0
Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA has accepted a supplemental new drug application for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer and granted it priority review.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In this video, Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of adding #darolutamide in metastatic hormone-sensitive prostate cancer. #pcsm | @UCIrvineHealth https://t.co/tYNkkyFQDZ